Phase II
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
ALZ-801 is administered orally and works by blocking the formation of neurotoxic soluble amyloid oligomers that later lead to cognitive decline in Alzheimer’s patients.
San Diego-based Endeavor BioMedicines closed on a Series B financing worth $101 million.
After reviewing available data, Bayer decided to abandon its Phase II development of eliapixant as the benefit-risk profile was not worthwhile.
Specialty vaccine company Valneva and Pfizer have reported positive Phase II data from their clinical trial evaluating a Lyme Disease vaccine candidate.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
The company indicated that its timeline for an accelerated approval request for its own Alzheimer’s drug, donanemab, was no longer on schedule for the first quarter after the CMS draft guidance.
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
PRESS RELEASES